Physician profile
Sheila Wright-Scott
NPI 1124023999
$903.43
in general payments reported to CMS, 2019-2025
12 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $72.77 · 2021: $90.28 · 2022: $156 · 2023: $34.85 · 2024: $294 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $401.26 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $89.14 | 2022 | |
| Aerie Pharmaceuticals, INC. | $79.90 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $63.94 | 2021-2024 | Acthar |
| Allergan, INC. | $50.75 | 2020-2021 | |
| Abbvie INC. | $41.70 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $35.83 | 2024 | Rayone Spheric, Rayner Cataract Set 1, Rayone Aspheric |
| Horizon Therapeutics Plc | $34.85 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $34.14 | 2025 | |
| Dompe US, INC. | $32.22 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $24.84 | 2022 | |
| Glaukos Corporation | $14.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Wright-Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.